Biologics in Inflammatory and Immunomediated Arthritis

Author(s): Michele M. Luchetti*, Devis Benfaremo, Armando Gabrielli

Journal Name: Current Pharmaceutical Biotechnology

Volume 18 , Issue 12 , 2017

Become EABM
Become Reviewer
Call for Editor


Background: Biologic drugs, introduced in clinical practice almost twenty years ago, represent nowadays a prominent treatment option in patients with chronic inflammatory arthritis, such as Rheumatoid Arthritis, Psoriatic Arthritis and Spondyloarthritis, that include ankylosing spondylitis and non-radiographic axial spondyloarthritis.

Methods: Several compounds targeting different pathways have been marketed and approved for the treatment of inflammatory arthritis, with a significant impact on the clinical outcomes and the natural history of the diseases.

Results: There are currently seven classes of biologics that are available for the treatment of inflammatory arthritis, each inhibiting a different aspect of the immune-driven inflammatory pathway.

They include:

• Tumor Necrosis Factor (TNF) inhibitors (infliximab, adalimumab, etanercept, golimumab and certolizumab pegol);

• Interleukin-1 (IL-1) receptor antagonists (anakinra);

• Interleukin-6 (IL-6) inhibition (tocilizumab);

• Interleukin-12/23 (IL23) inhibition (ustekinumab);

• Interleukin-17 (IL-17) inhibition (secukinumab);

• B-cell inhibition (anti-CD20, rituximab);

• T-cell costimulation inhibition (anti-CTLA-4, abatacept).

Conclusion: In this review, we will focus on the role of biologic drugs in the treatment strategies for inflammatory arthritis.

Keywords: Biologic drugs, TNF inhibitors, rheumatoid arthritis, spondyloarthritis, psoriatic arthritis, efficacy, safety.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2017
Page: [989 - 1007]
Pages: 19
DOI: 10.2174/1389201019666171226151852
Price: $65

Article Metrics

PDF: 89
HTML: 14